Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma

Exosomes are 60–150 nm small extracellular vesicles (EVs) released by most cells. Tumor-cell-derived exosomes, used as a vaccine, elicit a specific cytotoxic response against tumor cells, usually with a greater immunogenicity than tumor-cell lysates. However, the number of exosomes isolated from c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocozza, Federico, Menay, Florencia, Tsacalian, Rodrigo Farid, Elisei, Analia, Sampedro, Pura, Soria, Ivana, Waldner, Claudia Inés, Gravisaco, María José, Mongini, Claudia
Formato: Artículo
Lenguaje:Inglés
Publicado: Elsevier 2019
Materias:
Acceso en línea:http://hdl.handle.net/20.500.12123/4586
https://www.sciencedirect.com/science/article/pii/S0264410X19301872?via%3Dihub
https://doi.org/10.1016/j.vaccine.2019.02.004
_version_ 1855483461340495872
author Cocozza, Federico
Menay, Florencia
Tsacalian, Rodrigo Farid
Elisei, Analia
Sampedro, Pura
Soria, Ivana
Waldner, Claudia Inés
Gravisaco, María José
Mongini, Claudia
author_browse Cocozza, Federico
Elisei, Analia
Gravisaco, María José
Menay, Florencia
Mongini, Claudia
Sampedro, Pura
Soria, Ivana
Tsacalian, Rodrigo Farid
Waldner, Claudia Inés
author_facet Cocozza, Federico
Menay, Florencia
Tsacalian, Rodrigo Farid
Elisei, Analia
Sampedro, Pura
Soria, Ivana
Waldner, Claudia Inés
Gravisaco, María José
Mongini, Claudia
author_sort Cocozza, Federico
collection INTA Digital
description Exosomes are 60–150 nm small extracellular vesicles (EVs) released by most cells. Tumor-cell-derived exosomes, used as a vaccine, elicit a specific cytotoxic response against tumor cells, usually with a greater immunogenicity than tumor-cell lysates. However, the number of exosomes isolated from culture cells is limited. In recent studies, it was observed that cells respond to different stressor stimuli such as cytotoxic drugs, hypoxia, acidosis, or radiation by increasing the release of EVs. In this study, using the murine LBC T-cell lymphoma, we found that cyclophosphamide significantly increased EVs yield. These EVs express exosome marker proteins such as TSG-101, CD9, CD81, and CD63. Furthermore, similar humoral and cellular immune responses were induced in vivo by EVs isolated from LBC-tumor cells whether they were grown under normal culture conditions (EVs C) or in the presence of cyclophosphamide (EVs CTX). Mice vaccinated either with EVs C or EVs CTX were similarly protected against an intraperitoneal challenge with LBC tumor cells. CD4+ and CD8+ IFN-c secreting cells were induced in immunized mice and a specific cytotoxic cellular immune response was elicited in vitro. These results demonstrate that a Th1 response was induced by immunization with the EVs. Our findings suggest that treatment of tumor cells with cyclophosphamide is a useful method to enhance the secretion of EVs in sensitive cell lines without altering their antitumor properties and thus may be used to produce antigens for future design of cancer vaccines.
format Artículo
id INTA4586
institution Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina)
language Inglés
publishDate 2019
publishDateRange 2019
publishDateSort 2019
publisher Elsevier
publisherStr Elsevier
record_format dspace
spelling INTA45862021-01-11T16:34:19Z Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma Cocozza, Federico Menay, Florencia Tsacalian, Rodrigo Farid Elisei, Analia Sampedro, Pura Soria, Ivana Waldner, Claudia Inés Gravisaco, María José Mongini, Claudia Ciclofosfamida Neoplasmas Respuesta Inmunológica Linfoma Vacuna Linfocitos-t Cyclophosphamide Neoplasms Immune Response Lymphoma Vaccines T-lymphocytes Extracellular Vesicles Exosomes Vesículas Extracelulares Exosomas Exosomes are 60–150 nm small extracellular vesicles (EVs) released by most cells. Tumor-cell-derived exosomes, used as a vaccine, elicit a specific cytotoxic response against tumor cells, usually with a greater immunogenicity than tumor-cell lysates. However, the number of exosomes isolated from culture cells is limited. In recent studies, it was observed that cells respond to different stressor stimuli such as cytotoxic drugs, hypoxia, acidosis, or radiation by increasing the release of EVs. In this study, using the murine LBC T-cell lymphoma, we found that cyclophosphamide significantly increased EVs yield. These EVs express exosome marker proteins such as TSG-101, CD9, CD81, and CD63. Furthermore, similar humoral and cellular immune responses were induced in vivo by EVs isolated from LBC-tumor cells whether they were grown under normal culture conditions (EVs C) or in the presence of cyclophosphamide (EVs CTX). Mice vaccinated either with EVs C or EVs CTX were similarly protected against an intraperitoneal challenge with LBC tumor cells. CD4+ and CD8+ IFN-c secreting cells were induced in immunized mice and a specific cytotoxic cellular immune response was elicited in vitro. These results demonstrate that a Th1 response was induced by immunization with the EVs. Our findings suggest that treatment of tumor cells with cyclophosphamide is a useful method to enhance the secretion of EVs in sensitive cell lines without altering their antitumor properties and thus may be used to produce antigens for future design of cancer vaccines. Instituto de Virología Fil: Cocozza, Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Menay, Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Tsacalian, Rodrigo Farid. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Elisei, Analia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Sampedro, Pura. Universidad de Morón. Facultad de Ciencias Exactas, Químicas y Naturales; Argentina Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Waldner, Claudia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Gravisaco, María José. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Mongini, Claudia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Morón. Facultad de Ciencias Exactas, Químicas y Naturales; Argentina 2019-03-13T13:08:41Z 2019-03-13T13:08:41Z 2019-03 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/4586 https://www.sciencedirect.com/science/article/pii/S0264410X19301872?via%3Dihub 0264-410X https://doi.org/10.1016/j.vaccine.2019.02.004 eng info:eu-repo/semantics/restrictedAccess application/pdf Elsevier Vaccine 37 (12) : 1565-1576. (14 March 2019)
spellingShingle Ciclofosfamida
Neoplasmas
Respuesta Inmunológica
Linfoma
Vacuna
Linfocitos-t
Cyclophosphamide
Neoplasms
Immune Response
Lymphoma
Vaccines
T-lymphocytes
Extracellular Vesicles
Exosomes
Vesículas Extracelulares
Exosomas
Cocozza, Federico
Menay, Florencia
Tsacalian, Rodrigo Farid
Elisei, Analia
Sampedro, Pura
Soria, Ivana
Waldner, Claudia Inés
Gravisaco, María José
Mongini, Claudia
Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
title Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
title_full Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
title_fullStr Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
title_full_unstemmed Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
title_short Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
title_sort cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine t cell lymphoma
topic Ciclofosfamida
Neoplasmas
Respuesta Inmunológica
Linfoma
Vacuna
Linfocitos-t
Cyclophosphamide
Neoplasms
Immune Response
Lymphoma
Vaccines
T-lymphocytes
Extracellular Vesicles
Exosomes
Vesículas Extracelulares
Exosomas
url http://hdl.handle.net/20.500.12123/4586
https://www.sciencedirect.com/science/article/pii/S0264410X19301872?via%3Dihub
https://doi.org/10.1016/j.vaccine.2019.02.004
work_keys_str_mv AT cocozzafederico cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT menayflorencia cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT tsacalianrodrigofarid cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT eliseianalia cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT sampedropura cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT soriaivana cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT waldnerclaudiaines cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT gravisacomariajose cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma
AT monginiclaudia cyclophosphamideenhancesthereleaseoftumorexosomesthatelicitaspecificimmuneresponseinvivoinamurinetcelllymphoma